Stay updated on Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check72 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check86 days agoChange DetectedThe webpage has undergone significant changes, including the addition of new drug names and a revision of the study version. Notably, the detailed description of the Phase 1b study for pancreatic adenocarcinoma has been removed, which may impact the understanding of the study's purpose and methodology.SummaryDifference38%
Stay in the know with updates to Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.